Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03301168 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary completion date: Feb 2020 to May 2021Primary endpoints: 1 to 2 · Completion date: Feb 2035 to May 2034 · Interventions: AP1903 (Drug), BPX-501 T cells (Biological) to BPX-501 T cells (Biological), Rimiducid (Drug) · 3 morev17Show 6 more changesShow less
Primary endpoints: 1 to 2
Completion date: Feb 2035 to May 2034
Interventions: AP1903 (Drug), BPX-501 T cells (Biological) to BPX-501 T cells (Biological), Rimiducid (Drug)
NotablePrimary completion date: Jun 2019 to Feb 2020Completion date: Dec 2020 to Feb 2021v14Show 1 more changeShow less
Completion date: Dec 2020 to Feb 2021
Show 12 earlier versionsHide 12 earlier versions
MinorRe-verified, no change to tracked fieldsv13
MinorTrial status: Recruiting to Active, Not RecruitingSite details revised at 10 of 10 sitesv12Show 1 more changeShow less
Site details revised at 10 of 10 sites
MinorPrimary completion date: Dec 2018 to Jun 2019v11
MinorSite details revised at 1 of 10 sitesv10
MinorRe-verified, no change to tracked fieldsv9
MinorInterventions: AP1903 (Drug), BPX-501 T cells and AP1903 (Biological) to AP1903 (Drug), BPX-501 T cells (Biological)v8
NotablePrimary endpoint revisedCompletion date: Dec 2019 to Dec 2020 · Secondary endpoints expanded, about 12 words · Site contacts updated at 2 of 10 sites · 3 morev7Show 6 more changesShow less
NotableEnrollment target: 175 to 120Study sites: 1 to 10v2Show 1 more changeShow less
Study sites: 1 to 10
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).